Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments.
OBJECTIVE
An anti-angiogenic state has been implicated in the pathophysiology of preeclampsia, fetal growth restriction and fetal death. Vascular endothelial growth factor (VEGF), an indispensible angiogenic factor for embryonic and placental development exerts its angiogenic properties through the VEGF receptor (VEGFR)-2. A soluble form of this protein (sVEGFR-2) has been recently detected in maternal blood. The aim of this study was to determine if fetal death was associated with changes in the concentrations of sVEGFR-2 in maternal plasma and amniotic fluid.


METHODS
Maternal plasma was obtained from patients with fetal death (n = 59) and normal pregnant women (n = 134). Amniotic fluid was collected from 36 patients with fetal death and the control group consisting of patients who had an amniocentesis and delivered at term (n = 160). Patients with fetal death were classified according to the clinical circumstances into the following groups: (1) unexplained; (2) preeclampsia and/or placental abruption; (3) chromosomal and/or congenital anomalies. Plasma and amniotic fluid concentrations of sVEGFR-2 were determined by ELISA. Non-parametric statistics and logistic regression analysis were applied.


RESULTS
(1) Patients with a fetal death had a significantly lower median plasma concentration of sVEGFR-2 than normal pregnant women (p < 0.001). The median plasma concentration of sVEGFR-2 in patients with unexplained fetal death and in those with preeclampsia/abruption, but not that of those with congenital anomalies, was lower than that of normal pregnant women (p = 0.006, p < 0.001 and p = 0.2, respectively); (2) the association between plasma sVEGFR-2 concentrations and preterm unexplained fetal death remained significant after adjusting for potential confounders (OR: 3.2; 95% CI: 1.4-7.3 per each quartile decrease in plasma sVEGFR-2 concentrations); (3) each subgroup of fetal death had a higher median amniotic fluid concentration of sVEGFR-2 than the control group (p < 0.001 for each); (4) the association between amniotic fluid sVEGFR-2 concentrations and preterm unexplained fetal death remained significant after adjusting for potential confounders (OR: 15.6; 95% CI: 1.5-164.2 per each quartile increase in amniotic fluid sVEGFR-2 concentrations); (5) among women with fetal death, there was no relationship between maternal plasma and amniotic fluid concentrations of sVEGFR-2 (Spearman Rho: 0.02; p = 0.9).


CONCLUSIONS
Pregnancies with a fetal death, at the time of diagnosis, are characterized by a decrease in the maternal plasma concentration of sVEGFR-2, but an increase in the amniotic fluid concentration of this protein. Although a decrease in sVEGFR-2 concentration in maternal circulation depends upon the clinical circumstances of fetal death, an increase in sVEGFR-2 concentration in amniotic fluid seems to be a common feature of fetal death. It remains to be determined if the perturbation in sVEGFR-2 concentrations in maternal and fetal compartments observed herein preceded the death of a fetus.
Perinatology Research Branch, NICHD, NIH, DHHS, Bethesda, Maryland, USA.
Tinnakorn
T
Chaiworapongsa
Juan Pedro
JP
Kusanovic
Zeynep Alpay
ZA
Savasan
Shali
S
Mazaki-Tovi
Sun Kwon
SK
Kim
Edi
E
Vaisbuch
Adi L
AL
Tarca
Pooja
P
Mittal
Giovanna
G
Ogge
Ichchha
I
Madan
Zhong
Z
Dong
Lami
L
Yeo
Sonia S
SS
Hassan
Roberto
R
Romero
D000037:Abruptio Placentae / Q000097:blood / Q000453:epidemiology / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry / Q000378:metabolism; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D005313:Fetal Death / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D008431:Maternal-Fetal Exchange / Q000502:physiology; D009994:Osmolar Concentration; D021041:Placental Circulation / Q000502:physiology; D011225:Pre-Eclampsia / Q000097:blood / Q000453:epidemiology / Q000378:metabolism; D011247:Pregnancy; D012995:Solubility; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000032:analysis / Q000097:blood* / Q000378:metabolism / Q000502:physiology; D055815:Young Adult
D040301:Vascular Endothelial Growth Factor Receptor-2